PepGen Inc.
PepGen Inc. (Nasdaq: PEPG) is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Its proprietary Enhanced Delivery Oligonucleotide (EDO) platform uses cell-penetrating peptides conjugated to oligonucleotide medicines to support delivery into… From the company’s description.
In fiscal 2025, PepGen Inc. reported a net loss of $89.66M. Operations used $81.64M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What PepGen Inc. does
In the company’s own words
PepGen Inc. (Nasdaq: PEPG) is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Its proprietary Enhanced Delivery Oligonucleotide (EDO) platform uses cell-penetrating peptides conjugated to oligonucleotide medicines to support delivery into cells and their nuclei. PepGen’s lead candidate, PGN-EDODM1, is being developed for myotonic dystrophy type 1 (DM1). It is designed to bind expanded repeats in DMPK messenger RNA, freeing the MBNL1 protein and addressing disease-related RNA mis-splicing without degrading the DMPK transcript. The program includes FREEDOM, a completed Phase 1 study; FREEDOM2, a Phase 2 multiple-dose study; and an open-label extension study. PepGen’s work is primarily focused on PGN-EDODM1, while it also develops the EDO platform for potential use with other therapeutic cargos and in additional disease areas. The company’s platform technology originated in more than a decade of academic research at the Medical Research Council Laboratory of Molecular Biology and the University of Oxford.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1835597
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns PepGen Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · PepGen Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do PepGen Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of PepGen Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in PepGen Inc.'s last four quarterly filings that the numbers alone won't show?”